tiziana-logo.png
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
June 17, 2021 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology,...
tiziana-logo.png
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
June 02, 2021 02:00 ET | Tiziana Life Sciences Plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION...
tiziana-logo.png
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers
May 26, 2021 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for...
tiziana-logo.png
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
May 25, 2021 02:00 ET | Tiziana Life Sciences Plc
The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical...
tiziana-logo.png
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
May 07, 2021 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and...
tiziana-logo.png
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
May 05, 2021 02:00 ET | Tiziana Life Sciences Plc
Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either alone or in combination with a tyrosine...
tiziana-logo.png
Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
April 27, 2021 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.
April 13, 2021 07:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"),...
tiziana-logo.png
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
March 30, 2021 08:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences plc: Accustem Update
March 30, 2021 07:35 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and...